Health Catalyst (HCAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended March 2025, Health Catalyst (HCAT) reported revenue of $79.41 million, up 6.3% over the same period last year. EPS came in at $0.01, compared to $0.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $79.25 million, representing a surprise of +0.21%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.01.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Health Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Professional services: $27.93 million versus $28.04 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.6% change. Revenue- Technology: $51.48 million compared to the $51.21 million average estimate based on five analysts. The reported number represents a change of +9.6% year over year. Adjusted Gross Profit- Professional Services: $4.44 million versus $3.78 million estimated by five analysts on average. Adjusted Gross Profit- Technology: $34.61 million compared to the $33.32 million average estimate based on five analysts. View all Key Company Metrics for Health Catalyst here>>>Shares of Health Catalyst have returned +6.5% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Health Catalyst, Inc. (HCAT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks